

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau9906182-2
IP05's copy!

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 261/04, A61K 31/42	A1	(11) International Publication Number: WO 98/57939 (43) International Publication Date: 23 December 1998 (23.12.98)
(21) International Application Number: PCT/US98/12367 (22) International Filing Date: 12 June 1998 (12.06.98) (30) Priority Data: 60/049,712 16 June 1997 (16.06.97) US 60/049,633 16 June 1997 (16.06.97) US 60/080,278 1 April 1998 (01.04.98) US (71) Applicant: THE DU PONT MERCK PHARMACEUTICAL COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). (72) Inventors: MAURIN, Michael, B.; 28 Country Gates Drive, Wilmington, DE 19810 (US). MA, Philip; 29 Constitution Drive, Chadds Ford, PA 19317 (US). MELONI, David, J.; 34 Fantail Court, New Castle, DE 19720 (US). PESTI, Jaan, A.; 605 Country Club Drive, Wilmington, DE 19805 (US). ROSSANO, Lucius, T.; 7 West Ridge Court, Newark, DE 19711 (US). WARD, Randall, K.; 5111 East Brigantine Court, Wilmington, DE 19808 (US). YIN, Jianguo; 19 Signal Hill Drive, Hockessin, DE 19809 (US). ZHANG, Lin-Hua; 90 Gilliotti Road, New Fairfield, CT 06812 (US).		(74) Agent: LARSEN, Scott, K.; The du Pont Merck Pharmaceutical Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US). (81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: CRYSTALLINE ROXIFIBAN (57) Abstract The potent platelet glycoprotein IIb/IIIa antagonist, roxifiban, is produced in crystalline form. Crystalline roxifiban exists in two polymorphic forms, designated Form 1 and Form 2. These polymorphic forms are characterized by x-ray powder diffraction and solid-state carbon NMR. Pharmaceutical compositions and methods for the treatment or prevention of diseases mediated by platelet aggregation are described.		